Advertisement

Topics

Zynquista becomes second SGLT inhibitor approved for Type 1 diabetes in Europe

06:56 EDT 13 May 2019 | Pharmaceutical Technology

Sanofi and Lexicon’s sodium-glucose cotransporter (SGLT) inhibitor, Zynquista (sotagliflozin), has recently gained approval for use in type 1 diabetes (T1D)...
Read More...

The post Zynquista becomes second SGLT inhibitor approved for Type 1 diabetes in Europe appeared first on Pharmaceutical Technology.

Original Article: Zynquista becomes second SGLT inhibitor approved for Type 1 diabetes in Europe

NEXT ARTICLE

More From BioPortfolio on "Zynquista becomes second SGLT inhibitor approved for Type 1 diabetes in Europe"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...